Google, DeepMind, Artificial Intelligence, Big Data, UK, COVID-19, Immortality | |
Anonymous Coward User ID: 78612646 Canada 06/07/2020 07:22 PM Report Abusive Post Report Copyright Violation | |
Anonymous Coward User ID: 77977236 Canada 06/08/2020 04:03 PM Report Abusive Post Report Copyright Violation | (November 12, 2019) Meet the Startup: Chronomics’ epigenetics out of the lab "At Chronomics, we are defining the objective measures of health that go beyond blunt measures of biological age and have the power to support the longevity space through provision of tractable measures of efficacy and impact. The longevity sector is hugely important for the future of health globally and we are excited to be delivering the tools to support the companies developing the therapeutics and interventions that will define the future of prevention." [link to www.longevity.technology (secure)] (June 7, 2020) New saliva test could deliver Covid-19 result within one hour The tests work by people spitting into a tube and posting the sample to a lab A new saliva test could help the government meet its target of working out whether someone has coronavirus within 24 hours. The government is in talks with British company Chronomics about rolling out the test which would involve people who are suspected to have Covid-19 spitting into a tube and posting the sample to a lab. The company is aiming to produce test results within one hour of the samples arriving at labs. [link to inews.co.uk (secure)] |
Halfing User ID: 78568195 Hungary 06/08/2020 06:41 PM Report Abusive Post Report Copyright Violation | |
Anonymous Coward User ID: 77482237 Netherlands 06/15/2020 05:24 PM Report Abusive Post Report Copyright Violation | (June 14, 2020) Coronavirus tests could be carried out at work under Matt Hancock’s plans Coronavirus tests could be carried out at work with results within two hours by the autumn, officials claim. The Health Secretary has said officials are in talks with businesses about how they could run their own testing programmes as they re-open. GP surgeries, dentists, prisons, airports and ports may be first in line to offer workplace testing. The ambitious plans – revealed at an industry briefing last week – aim to boost testing figures to expand Boris Johnson’s 200,000-a-day target. Ministers are also looking at rolling out a series of new tests by the autumn, such as the saliva test which health chiefs have been validating in recent weeks. Research suggests saliva tests are more accurate than swabs used now because there is less room for errors in sampling. All it requires is some saliva in a tube. The Government is reportedly in talks with epigenetics company Chronomics about its saliva test – two months after the US approved a similar one. [link to www.todaynewspost.com (secure)] |
Anonymous Coward User ID: 79034649 United Kingdom 06/15/2020 05:35 PM Report Abusive Post Report Copyright Violation | i think cov19 is the first AI designed hoax: it operates deeply on so many levels and furthers so many long desired agenda's also very hard to prove the hoax as long as you own the global media. the many dissenting medical staff do not have a voice Q: what happened to this years "flu season" ? |
Anonymous Coward User ID: 77795952 Sweden 08/07/2020 12:16 PM Report Abusive Post Report Copyright Violation | Google Cloud President Tariq Shaukat heard "an overriding sentiment" when he spoke with pharma and life science executives recently at the annual J.P. Morgan Healthcare Conference: The pharma industry is behind in modernizing and using digital technology. To that end, his company is partnering with Accenture on an open architecture platform to accelerate discovery, research and delivery for pharma and life sciences companies. Accenture’s platform, called Intient, strikes an exclusive partnership with Google Cloud to migrate all parts of the now seven-year-old technology onto a single end-to-end architecture with Google. The intent is to combine Accenture’s industry experience and connections with Google's data analytics and artificial intelligence capabilities. Intient clients include GlaxoSmithKline, Pfizer, Bayer and many other top 25 pharma companies, said Simon Eaves, group chief executive of products at Accenture. [link to www.fiercepharma.com (secure)] |
Anonymous Coward User ID: 77839377 United States 08/07/2020 01:57 PM Report Abusive Post Report Copyright Violation | |
Anonymous Coward User ID: 76658155 Romania 08/18/2020 05:13 AM Report Abusive Post Report Copyright Violation | |
Anonymous Coward User ID: 77940018 United States 09/13/2020 05:12 PM Report Abusive Post Report Copyright Violation | Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test. This will support the UK’s efforts to manage the continued reduction of COVID-19 and containment of new cases, now and through the winter cold and flu season. Under the agreement, an initial 450k LamPORE SARS-CoV-2 tests will be made available for use by a number of NHS testing laboratories. As well as providing a large number of tests for existing labs, the programme will help the UK to understand the different use cases for the technology, for example the potential asymptomatic screening of frontline staff. Because of its scalability, LamPORE has the potential to provide both: Large-scale screening to detect the virus in broader populations. Individuals being tested may be presymptomatic or asymptomatic, eg: - Regular screening of frontline workforces - Broad screening of a community/population in the event of an outbreak - Screening at the point of congregation eg transport hubs LamPORE is designed to be deployed on Oxford Nanopore’s desktop device (GridION) or palm-sized device (MinION Mk1C), providing the capacity of processing up to 15,000 samples a day or 2,000 samples a day respectively. In addition to a test for SARS-CoV-2, the virus that causes COVID-19, Oxford Nanopore is currently developing LamPORE to test for multiple pathogens within a single sample, including influenza A (H1N1 and H3N2), influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2. [link to www.news-medical.net (secure)] (August 14, 2020) Researchers Use Nanopore Sequencing Technology to Complete First Gapless End-to-End Assembly of Human X Chromosome Using nanopore sequencing technology from multiple companies, researchers at the University of California Santa Cruz Genomics Institute (UCSC Genomics Institute) have produced what they say is the first telomere-to-telomere or end-to-end map of the human X chromosome. This could prove to be a major milestone for genomics research and help scientists gain a better understanding of certain genetic conditions. The completely gapless DNA sequencing was produced by using new sequencing technologies that enable much longer reads of strings of DNA base pairs. In the past, most sequencing technologies produced relatively short reads of each sequence, which then had to be painstakingly pieced together to assemble the complete genome. Nanopore sequencing technology from Oxford Nanopore Technologies was combined with sequencing technologies from Pacific Biosciences (PacBio) and Illumina, as well as with optical maps from Bionano Genomics, to produce the results of the research. The combination of these technologies allowed the UCSC team to produce a whole-genome sequence assembly with no gaps and with a previously unforeseen level of accuracy. Besides the advantages of providing ultra-long reads, nanopore sequencing can also detect bases that have been modified by methylation, a biological process by which methyl groups are added to the DNA molecule. Methylation is an epigenetic change that can alter the activity of a DNA segment without changing the sequence, and can have important effects on the DNA structure and gene expression. [link to www.darkdaily.com (secure)] |
Anonymous Coward User ID: 79441711 United Kingdom 10/18/2020 02:22 PM Report Abusive Post Report Copyright Violation | (October 15, 2020) Google & Oracle to Monitor Americans Who Get Warp Speed’s Covid-19 Vaccine for up to Two Years During an interview with the Wall Street Journal published last Friday, the “captain” of Operation Warp Speed, career Big Pharma executive Moncef Slaoui, confirmed that the millions of Americans who are set to receive the project’s Covid-19 vaccine will be monitored via “incredibly precise . . . tracking systems” that will “ensure that patients each get two doses of the same vaccine and to monitor them for adverse health effects.” Slaoui also noted that tech giants Google and Oracle have been contracted as part of this “tracking system” but did not specify their exact roles beyond helping to “collect and track vaccine data.” The day before the Wall Street Journal interview was published, the New York Times published a separate interview with Slaoui where he referred to this “tracking system” as a “very active pharmacovigilance surveillance system.” [link to www.thelastamericanvagabond.com (secure)] |
Anonymous Coward User ID: 79417936 United Kingdom 11/04/2020 03:42 PM Report Abusive Post Report Copyright Violation | |
Anonymous Coward User ID: 79581286 Netherlands 11/04/2020 04:16 PM Report Abusive Post Report Copyright Violation | |